Stent to treat pancreatic cysts approved

(HealthDay)—The Axios Stent and Delivery System has been approved by the U.S. Food and Drug Administration to treat infected pancreatic cysts that won't drain on their own and could become life threatening, the FDA said in a news release.

The pancreas, found in the upper abdomen behind the stomach, produces insulin that helps regulate and helps digestion. If pancreatic ducts become blocked from gallstones or injury, enzymes that back up into the organ can cause formation of pancreatic pseudocysts.

Most resolve on their own, but some become infected and can lead to a life-threatening blood infection, the FDA said.

The Axios stent is a wire mesh tube that can expand to more than 1/2-inch diameter. It was evaluated among 33 clinical study participants who had a pancreatic pseudocyst at least six centimeters in diameter. Some 86 percent of pseudocysts treated shrank by half or more, the FDA said.

The most common side effects of the stent included , nausea and vomiting.

The device is produced by Xlumena Inc. of Mountain View, Calif.

More information: Visit Medline Plus to learn more about pancreatic pseudocysts.

add to favorites email to friend print save as pdf

Related Stories

Two pancreatic-enzyme products approved

Mar 02, 2012

(HealthDay) -- Two drugs that supplement the digestion-aiding actions of pancreatic enzymes have been approved by the U.S. Food and Drug Administration, the agency said Thursday in a news release.

Imbruvica approved for mantle cell lymphoma

Nov 13, 2013

(HealthDay)—Imbruvica (ibrutinib) has been approved by the U.S. Food and Drug Administration to treat mantle cell lymphoma (MCL), a rare but aggressive form of blood cancer.

Signifor approved for Cushing's disease

Dec 17, 2012

(HealthDay)—Signifor (pasireotide diaspartate) has been approved by the U.S. Food and Drug Administration to treat Cushing's disease in cases that cannot be treated by surgery.

Recommended for you

Mirabegron for overactive bladder: Added benefit not proven

7 hours ago

Mirabegron (trade name: Betmiga) has been approved since December 2012 for the treatment of adults with overactive bladder. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products ...

Novartis Japan admits concealing drug side effects

Sep 01, 2014

The Japanese unit of Swiss pharma giant Novartis has admitted it did not report more than 2,500 cases of serious side effects in patients using its leukaemia and other cancer drugs, reportedly including some fatalities.

Most US babies get their vaccines, CDC says

Aug 28, 2014

(HealthDay)—The vast majority of American babies are getting the vaccines they need to protect them from serious illnesses, federal health officials said Thursday.

User comments